. The combined data provide an authoritative, comprehensive, and timely national assessment of influenza virus and disease activity and are relied upon by international and national public health authorities and physicians. The surveillance reports are updated each week during the months of October-May [3] . We also wish to correct any misconceptions fostered by Dr. Hudson's letter [1] that the CDC was involved with the formation of the National Flu Surveillance Network (NFSN). CDC does not endorse the NFSN and is not associated with this enterprise. The NFSN is a proprietary commercial system that promotes the sale of the ZstatFlu rapid diagnostic test (ZymeTx) and relies exclusively upon results of this test. The ZstatFlu test has reported sensitivities of 65%-96% and specificities of 63%-92% compared with viral culture [4] [5] [6] [7] . Reported positive predictive values of the test, compared with viral culture, had a range of 59%-79%. The test is least accurate when the prevalence of circulating influenza viruses is low, as is the situation during the early and late parts of the influenza season. This test also does not distinguish between the presence of influenza A or B viruses, which is a matter of importance for institutions, such as nursing homes, that frequently use amantadine or rimantadine to control influenza A outbreaks. For chemoprophylaxis of influenza B outbreaks, the only currently approved antiviral drug is oseltamivir.
